Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy.

Ambrosius, Björn; Gold, Ralf; Chan, Andrew; Faissner, Simon (2019). Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy. Neurology: Neuroimmunology and Neuroinflammation, 6(3), e551. Wolters Kluwer Health 10.1212/NXI.0000000000000551

Preview

Text e551.full.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (381kB) | Preview

Today, HIV-infected (HIV+) patients can be treated efficiently with combined antiretroviral therapy (cART), leading to long-term suppression of viral load, in turn increasing life expectancy. While cART reduced the occurrence of HIV-associated dementia, the prevalence of subtle forms of HIV-associated neurocognitive disorders (HAND) is unchanged. This is related to persistent immune activation within the CNS, which is not addressed by cART. Pathologic processes leading to HAND consist of the release of proinflammatory cytokines, chemokines, reactive oxygen metabolites and glutamate, and the release of HIV proteins. Some of those processes can be targeted using medications with immunomodulatory and neuroprotective properties such as dimethyl fumarate, teriflunomide, or minocycline. In this review, we will summarize the knowledge about key pathogenic processes involved in HAND and potential therapeutic avenues to target HAND.

Interest & Impact

Downloads

137 since deposited on 14 Nov 2019
17 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item